
The third time seems to be the charm for drugmakers Bristol-Myers Squibb and Gilead Sciences, who struck out in two previous attempts to craft a single-pill, once-daily antiretroviral regimen. The companies on Monday announced they’ve successfully combined the drugs Sustiva and Truvada into a single formulation. Truvada is already a combination pill containing Emtriva and Viread. The companies plan to file for Food and Drug Administration approval of the resulting single-pill regimen in the second quarter of 2006. Should the FDA approve the pill, it would be the only one-pill, once-daily full antiretroviral regimen available in the United States. The medication could be available to consumers before the end of the year.
“The advancement of our fixed-dose regimen represents an important step forward in the further simplification of HIV treatment,” said John C. Martin, president and chief executive officer of Gilead Sciences in a press statement. “Gilead and Bristol-Myers Squibb share a commitment to the treatment of HIV, a disease for which significant unmet medical need continues to exist, and we look forward to working with regulatory authorities.”
Gilead and Bristol-Myers Squibb announced in December 2004 that they planned to collaborate on a venture to combine Gilead’s Truvada with Bristol-Myers Squibb’s Sustiva into a single pill that would be taken just once daily. The first two attempts to combine the medications were unsuccessful, as the resulting combination pill did not have the same bioequivalence of the drugs dosed separately. The new pill uses bilayering technology to incorporate the drugs into a single fomulation, and studies show it has the same bioequivalence as the individual medications.
Health and Human Services guidelines recommend the combination of Sustiva and Truvada as a preferred nonnucleoside reverse transcriptase inhibitor–based regimen for treatment-naive HIV-positive adults. (Advocate.com)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.